Chimerix Cuts 26 Jobs To Preserve Cash
This article was originally published in Scrip
Executive Summary
Chimerix Inc. cut 20% of its workforce, or 26 jobs, to preserve $342.9m in cash while the company reevaluates the development of lead antiviral drug candidate brincidofovir for the prevention or treatment of cytomegalovirus (CMV) and other DNA viral infections in transplant patients.